JPWO2020176478A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020176478A5 JPWO2020176478A5 JP2021549595A JP2021549595A JPWO2020176478A5 JP WO2020176478 A5 JPWO2020176478 A5 JP WO2020176478A5 JP 2021549595 A JP2021549595 A JP 2021549595A JP 2021549595 A JP2021549595 A JP 2021549595A JP WO2020176478 A5 JPWO2020176478 A5 JP WO2020176478A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- inflammatory
- composition
- inflammatory agent
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809988P | 2019-02-25 | 2019-02-25 | |
| US62/809,988 | 2019-02-25 | ||
| PCT/US2020/019668 WO2020176478A1 (en) | 2019-02-25 | 2020-02-25 | Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022521428A JP2022521428A (ja) | 2022-04-07 |
| JPWO2020176478A5 true JPWO2020176478A5 (de) | 2023-03-06 |
Family
ID=72239885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549595A Pending JP2022521428A (ja) | 2019-02-25 | 2020-02-25 | 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220118089A1 (de) |
| EP (1) | EP3930687A4 (de) |
| JP (1) | JP2022521428A (de) |
| CN (1) | CN113710229A (de) |
| WO (1) | WO2020176478A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2603520A4 (de) * | 2010-08-10 | 2014-02-19 | Ecole Polytech | Erythrozytenbindende therapeutika |
| JP2021514661A (ja) * | 2018-03-05 | 2021-06-17 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
| SE545148C2 (en) * | 2020-06-29 | 2023-04-18 | Antaros Tracer Ab | Novel compounds for use in diagnosis and/or monitoring of fibrosis |
| US20240044915A1 (en) * | 2020-12-22 | 2024-02-08 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Use of stromal cell-derived factor 1 (sdf1) as a biomarker for diagnosing and treating severe acute respiratory distress syndrome (ards) |
| EP4352086A1 (de) * | 2021-06-03 | 2024-04-17 | The University of Chicago | Verfahren und zusammensetzungen zur behandlung von fibrose |
| CN116987202B (zh) * | 2023-09-27 | 2023-12-01 | 英特菲尔(成都)生物制品有限责任公司 | 一种具有抗炎舒缓活性的融合蛋白及其制备方法与应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| EP2899277A1 (de) | 2004-11-26 | 2015-07-29 | Pieris AG | Verbindung mit Affinität für das zytotoxische T-Lymphozyten-assoziierte Antigen (CTLA-4) |
| WO2009004339A2 (en) * | 2007-07-03 | 2009-01-08 | Imperial Innovations Limited | Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection |
| EP2352765B1 (de) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Bispezifischer einzelkettenantikörper mit kreuz-spezies-spezifischer einzeldomäne |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| WO2014176284A1 (en) * | 2013-04-22 | 2014-10-30 | Avelas Biosciences, Inc. | Selective drug delivery compositions and methods of use |
| PL3049439T3 (pl) | 2013-09-26 | 2020-07-13 | Ablynx N.V. | Bispecyficzne nanociała |
| KR101774150B1 (ko) * | 2016-04-08 | 2017-09-05 | 경희대학교 산학협력단 | BSA(Bovine serum albumin)와 진세노사이드의 결합체 및 이의 용도 |
| US20200270322A1 (en) * | 2016-10-14 | 2020-08-27 | Philogen S.P.A. | Novel interleukin 4 immunoconjugates |
| CA3047312A1 (en) * | 2016-12-15 | 2018-06-21 | The Brigham And Women's Hospital, Inc. | Tissue-based biologics for the treatment of inflammatory and autoimmune disorders |
| MX2019012579A (es) * | 2017-04-20 | 2020-07-28 | Univ Chicago | Métodos y composiciones para tratar el cáncer con péptidos de afinidad de mec ligados a anticuerpos inmunoterapéuticos. |
| JP2021514661A (ja) * | 2018-03-05 | 2021-06-17 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
-
2020
- 2020-02-25 EP EP20762257.2A patent/EP3930687A4/de active Pending
- 2020-02-25 WO PCT/US2020/019668 patent/WO2020176478A1/en unknown
- 2020-02-25 US US17/310,802 patent/US20220118089A1/en active Pending
- 2020-02-25 JP JP2021549595A patent/JP2022521428A/ja active Pending
- 2020-02-25 CN CN202080030419.5A patent/CN113710229A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ashkenazi et al. | Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. | |
| US8349323B2 (en) | Cytokine antagonists for neurological and neuropsychiatric disorders | |
| DE69233701T2 (de) | Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor | |
| US6235281B1 (en) | Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 | |
| Starnes Jr et al. | Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. | |
| DE3587597T2 (de) | Lymphotoxin, dafür kodierende Nukleinsäure, die Nukleinsäure enthaltenden Vektoren und damit transformierte Zellen, Verfahren zum Erhalten von Lymphotoxin und Lymphotoxin neutralisierender Antikörper. | |
| Berry et al. | The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases | |
| US7708995B2 (en) | Use of TNF-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus | |
| US7906481B2 (en) | Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus | |
| May et al. | Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6" neutralizing" antibodies in vivo. | |
| US7723357B2 (en) | Thalidomide and thalidomide derivatives for treating spinal disorders mediated by nucleus pulposus | |
| EP1476189A1 (de) | Verwendung von tnf-alpha-antagonisten als arznei mittel zur behandlung von patienten mit sepsis ohne totales organversagen | |
| US20030113318A1 (en) | TNF inhibition for the treatment of pre-menstrual syndrome and primary dysmenorrhea | |
| KR20010022900A (ko) | 인터루킨-18 결합 단백질, 이들의 제조방법 및 용도 | |
| US8119127B2 (en) | Cytokine antagonists for neurological and neuropsychiatric disorders | |
| JPWO2020176478A5 (de) | ||
| Abubakar et al. | The role of TNF-α and anti-TNF-α agents in the immunopathogenesis and management of immune dysregulation in primary immunodeficiency diseases | |
| US11667704B2 (en) | Anti-IL-17 antibody/TNFR ECD fusion protein and use thereof | |
| van der Poll et al. | Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia | |
| JP2023524866A (ja) | 抗ｉｌ－３３抗体の処方物 | |
| US20020025316A1 (en) | Pharmaceutical composition containing inhibitors of interferon-gamma | |
| US20170190768A1 (en) | Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease | |
| US7727520B2 (en) | Method of promoting the healing of a chronic wound | |
| Niewold et al. | Recombinant Human Tumour Necrosis Factor‐α (rhTNF‐α) and rhTNF‐α Analogue Enhance Amyloid Deposition in the Syrian Hamster | |
| Shukla et al. | Pharmacology of TNF inhibitors |